SCHEMBL3098375

SCHEMBL3098375

Cc1cc(CN(c2cn(-c3c(Cl)cc(C(F)(F)F)cc3Cl)nc2C#N)S(C)(=O)=O)no1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 6/20 0.37
GABRB2 P47870 6/20 0.37
MAPK1 P28482 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
NR1I2 O75469 1/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRE P78334 1/20 0.35
GABRA6 Q16445 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GABRG1 Q8N1C3 1/20 0.35
GABRG3 Q99928 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3105340 0.82 GABRA2 (0.39) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL3116573 0.81 GABRP (0.47) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL3109639 0.80 GABRB3 (0.37) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL3106252 0.79 GABRA2 (0.43) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL3106282 0.75 GABRA2 (0.38) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL3107735 0.74 GABRA2 (0.41) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL6055741 0.72 GABRA2 (0.45) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL13157523 0.71 GABRP (0.35) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL3098620 0.69 GABRA2 (0.43) GABRA2GABRB2GABRPGABRDNR1I2
SCHEMBL6055865 0.68 GABRA2 (0.45) GABRA2GABRB2GABRPGABRDNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803832-B2 N-(1-arylpyrazol-4L)sulfonamides and their use as parasiticides PFIZER INC. (US) 2010-09-28 US disclosed
US-7687533-B2 N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides PFIZER INC. (US) 2010-03-30 US disclosed
US-20100075956-A1 N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES PFIZER INC. (US) 2010-03-25 US disclosed
US-20080261940-A1 N-(1-Arylpyrazol-4L) Sulfonamides and their Use as Parasiticides ZOETIS LLC 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075956-A1 N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES ARSA, STS, SULT1E1 GABRA2 2277/4885GABRB2 2822/4885MAPK1 1719/4885
US-20080261940-A1 N-(1-Arylpyrazol-4L) Sulfonamides and their Use as Parasiticides ARSA, STS, SULT1E1 GABRA2 2277/4885GABRB2 2822/4885MAPK1 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.